169 related articles for article (PubMed ID: 27718158)
1. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.
Sacristán JA; Lizan L; Comellas M; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Dilla T
Adv Ther; 2016 Nov; 33(11):2059-2068. PubMed ID: 27718158
[TBL] [Abstract][Full Text] [Related]
2. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
Daroudi R; Mirzania M; Zendehdel K
Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
[TBL] [Abstract][Full Text] [Related]
3. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.
Dilla T; Lizan L; Paz S; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Sacristán JA
Patient Prefer Adherence; 2016; 10():1-7. PubMed ID: 26719677
[TBL] [Abstract][Full Text] [Related]
4. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
[TBL] [Abstract][Full Text] [Related]
5. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
6. Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France.
Protiére C; Baker R; Genre D; Goncalves A; Viens P
Med Decis Making; 2017 Jul; 37(5):555-566. PubMed ID: 28199180
[TBL] [Abstract][Full Text] [Related]
7. Should clinically meaningful outcomes in cancer be based on individual survival rather than median overall survival?
Sacristán JA; Dilla T; Garrido P; Avendaño C; Cruz-Hernández JJ; Espinosa J; Comellas M; Lizán L
J Comp Eff Res; 2017 Sep; 6(6):491-495. PubMed ID: 28959896
[TBL] [Abstract][Full Text] [Related]
8. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
Berry SR; Hubay S; Soibelman H; Martin DK
BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
[TBL] [Abstract][Full Text] [Related]
9. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
10. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
[TBL] [Abstract][Full Text] [Related]
11. Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.
Wong SK; Gondara L; Gill S
Curr Oncol; 2021 Nov; 28(6):4748-4755. PubMed ID: 34898584
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on Cost and Value in Cancer Care.
Saltz LB
JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
[No Abstract] [Full Text] [Related]
13. [Reflections about the efficiency criteria for cancer treatments during marketing authorization application].
Jeannin N; Blois-Da Conceição S; Protière C
Bull Cancer; 2013 Mar; 100(3):259-69. PubMed ID: 23501472
[TBL] [Abstract][Full Text] [Related]
14. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey.
Schrag D; Hanger M
J Clin Oncol; 2007 Jan; 25(2):233-7. PubMed ID: 17210946
[TBL] [Abstract][Full Text] [Related]
15. Oncologists' Views on Using Value to Guide Cancer Treatment Decisions.
Gidwani-Marszowski R; Nevedal AL; Blayney DW; Patel M; Kelly PA; Timko C; Ramchandran K; Murrell SS; Asch SM
Value Health; 2018 Aug; 21(8):931-937. PubMed ID: 30098670
[TBL] [Abstract][Full Text] [Related]
16. Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians.
de Kort SJ; Kenny N; van Dijk P; Gevers S; Richel DJ; Willems DL
Eur J Cancer; 2007 Sep; 43(13):1983-9. PubMed ID: 17616456
[TBL] [Abstract][Full Text] [Related]
17. How long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.
Kozminski MA; Neumann PJ; Nadler ES; Jankovic A; Ubel PA
Med Decis Making; 2011; 31(3):380-5. PubMed ID: 21088130
[TBL] [Abstract][Full Text] [Related]
18. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival.
Ubel PA; Berry SR; Nadler E; Bell CM; Kozminski MA; Palmer JA; Evans WK; Strevel EL; Neumann PJ
Health Aff (Millwood); 2012 Apr; 31(4):709-17. PubMed ID: 22492887
[TBL] [Abstract][Full Text] [Related]
19. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
20. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
